Fidaxomicin for the treatment of clostridium difficile infection (cdi) in at-risk patients with inflammatory bowel disease, fulminant cdi, renal impairment or hepatic impairment: a retrospective study of routine clinical use (anemone)

HIGHLIGHTS

• who: Maria J. G. T. Vehreschild from the Department I of Internal Medicine, University Hospital of Cologne Bonn-Cologne, Cologne, Germany have published the paper: Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE), in the Journal: (JOURNAL) of 01/06/2012
• what: The aim was to identify the proportion of fidaxomicin-treated patients with MCSIs. The ANEMONE study aimed to determine the prevalence of these conditions in patient populations treated with . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.